<DOC>
	<DOC>NCT00573547</DOC>
	<brief_summary>The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.</brief_summary>
	<brief_title>Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease</brief_title>
	<detailed_description>Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders. This study will test whether once-weekly Prozac leads to reduced symptoms of depression. Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Diagnosis of chronic renal failure and end stage renal disease Ongoing need for regular dialysis treatment Diagnosis of depression based on DSMIV Age tween 1965 years Inability to provide informed consent Medically or psychiatrically unstable, as defined by requiring inpatient treatment Pregnancy, nursing or refusal to use a reliable method of birth control in women Patients with known allergy to fluoxetine, or previous treatment failure of fluoxetine</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>depression</keyword>
	<keyword>chronic renal failures</keyword>
	<keyword>end stage renal disease</keyword>
</DOC>